UBS Group
SGMO

UBS Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

UBS Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$635K Buy
2,570,992
+1,546,517
+151% +$615K ﹤0.01% 5901
2025
Q4 		$430K Sell
1,024,475
-296,343
-22% -$157K ﹤0.01% 6174
2025
Q3 		$889K Buy
1,320,818
+71,809
+6% +$38.7K ﹤0.01% 5669
2025
Q2 		$676K Buy
1,249,009
+638,043
+104% +$379K ﹤0.01% 5766
2025
Q1 		$401K Buy
610,966
+276,805
+83% +$293K ﹤0.01% 6027
2024
Q4 		$341K Buy
334,161
+235,991
+240% +$431K ﹤0.01% 6110
2024
Q3 		$85K Buy
98,170
+12,956
+15% +$9.49K ﹤0.01% 6469
2024
Q2 		$30.5K Sell
85,214
-75,086
-47% -$40.6K ﹤0.01% 7043
2024
Q1 		$107K Buy
160,300
+18,111
+13% +$13.1K ﹤0.01% 6194
2023
Q4 		$77.2K Sell
142,189
-603,791
-81% -$278K ﹤0.01% 6328
2023
Q3 		$448K Buy
745,980
+649,133
+670% +$695K ﹤0.01% 4741
2023
Q2 		$126K Sell
96,847
-170,766
-64% -$233K ﹤0.01% 5831
2023
Q1 		$471K Sell
267,613
-324,441
-55% -$926K ﹤0.01% 4739
2022
Q4 		$1.86M Buy
592,054
+485,785
+457% +$1.89M ﹤0.01% 3461
2022
Q3 		$520K Sell
106,269
-91,347
-46% -$469K ﹤0.01% 4301
2022
Q2 		$818K Sell
197,616
-262,764
-57% -$1.14M ﹤0.01% 3889
2022
Q1 		$2.67M Buy
460,380
+51,968
+13% +$309K ﹤0.01% 3149
2021
Q4 		$3.06M Buy
408,412
+118,557
+41% +$1.03M ﹤0.01% 3334
2021
Q3 		$2.61M Buy
289,855
+174,571
+151% +$1.73M ﹤0.01% 3340
2021
Q2 		$1.38M Sell
115,284
-230,444
-67% -$2.61M ﹤0.01% 3909
2021
Q1 		$4.33M Buy
345,728
+306,841
+789% +$4.13M ﹤0.01% 2768
2020
Q4 		$607K Buy
38,887
+26,725
+220% +$313K ﹤0.01% 4449
2020
Q3 		$115K Sell
12,162
-137,934
-92% -$1.49M ﹤0.01% 5108
2020
Q2 		$1.34M Buy
150,096
+126,304
+531% +$1.17M ﹤0.01% 3257
2020
Q1 		$151K Buy
23,792
+6,317
+36% +$46.9K ﹤0.01% 4939
2019
Q4 		$147K Sell
17,475
-158,242
-90% -$1.46M ﹤0.01% 5797
2019
Q3 		$1.59M Buy
175,717
+76,912
+78% +$863K ﹤0.01% 3535
2019
Q2 		$1.06M Buy
98,805
+79,056
+400% +$841K ﹤0.01% 3713
2019
Q1 		$188K Sell
19,749
-308,410
-94% -$3.15M ﹤0.01% 4634
2018
Q4 		$3.77M Buy
328,159
+214,906
+190% +$2.67M ﹤0.01% 2432
2018
Q3 		$1.92M Buy
113,253
+36,690
+48% +$558K ﹤0.01% 3248
2018
Q2 		$1.09M Sell
76,563
-132,181
-63% -$2.2M ﹤0.01% 3717
2018
Q1 		$3.97M Buy
208,744
+198,017
+1,846% +$4.23M ﹤0.01% 2524
2017
Q4 		$176K Sell
10,727
-2,567
-19% -$38.2K ﹤0.01% 5006
2017
Q3 		$200K Sell
13,294
-17,264
-56% -$191K ﹤0.01% 4846
2017
Q2 		$269K Buy
30,558
+23,708
+346% +$152K ﹤0.01% 4553
2017
Q1 		$36K Sell
6,850
-11,531
-63% -$46.3K ﹤0.01% 5744
2016
Q4 		$56K Buy
18,381
+337
+2% +$1.23K ﹤0.01% 5733
2016
Q3 		$83K Sell
18,044
-16,180
-47% -$82.3K ﹤0.01% 5110
2016
Q2 		$198K Buy
34,224
+20,724
+154% +$132K ﹤0.01% 4541
2016
Q1 		$81K Sell
13,500
-693
-5% -$4.16K ﹤0.01% 5132
2015
Q4 		$129K Buy
14,193
+693
+5% +$5.34K ﹤0.01% 5013
2015
Q3 		$76K Sell
13,500
-3,800
-22% -$31.3K ﹤0.01% 5461
2015
Q2 		$192K Sell
17,300
-8,517
-33% -$110K ﹤0.01% 4904
2015
Q1 		$405K Sell
25,817
-1,469
-5% -$22.7K ﹤0.01% 4314
2014
Q4 		$415K Buy
+27,286
New +$331K ﹤0.01% 4355

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

UBS Group's SGMO Position: Q1 2026 in Review

UBS Group increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 151% in Q1 2026, buying an estimated $615K and bringing the position to 2,570,992 shares worth $635K. The position accounts for ﹤0.01% of the portfolio, ranked #5901.

UBS Group first reported a position in SGMO in Q4 2014 and has held it in 46 quarters since. The position peaked at $4.33M in Q1 2021. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • UBS Group held 2,570,992 shares of SANGAMO THERAPEUTICS INC worth $635K as of Q1 2026.
  • UBS Group bought 1,546,517 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $615K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5901 holding.
  • UBS Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's SANGAMO THERAPEUTICS INC position peaked at $4.33M in Q1 2021.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.